PRISM BioLab Co.,LTD (TYO:206A)

Revenue by Segment

Financials in millions JPY. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023
Drug Discovery Business	677.33M	305.62M	112.93M
Total	677.33M	305.62M	112.93M

Revenue by Geography

Financials in millions JPY. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023
Japan	110.00M	69.63M	68.04M
United States of America	523.50M	219.20M	11.78M
Switzerland	43.83M	16.79M	12.06M
France	-	-	21.05M
Total	677.33M	305.62M	112.93M

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 6, 2026

Data Sources Report a data error